featured
Partial and Nonresponders to OnabotulinumtoxinA Can Benefit From Anti-CGRP Monoclonal Antibodies
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
European Journal of Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Partial and Nonresponders to OnabotulinumtoxinA Can Benefit From Anti-CGRP Monoclonal Antibodies Preventive Treatment: A Real-World Evidence Study
Eur. J. Neurol. 2021 Mar 17;[EPub Ahead of Print], A Alpuente, VJ Gallardo, E Caronna, M Torres-Ferrús, P Pozo-RosichFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.